Leishmaniasis is an infection caused by various species of Leishmania protozoa, which are usually transmitted by phlebotomine female sandflies [1] . The disease is endemic in 88 countries throughout Latin America, Africa, Asia and southern Europe. Approximately 350 million people are thought to be at risk with a worldwide prevalence of 12 million and annual incidence of 2 million new cases [2] . Moreover, multiple factors such as the AIDS epidemic, increased international travel, a lack of effective vaccines, difficulties in controlling vectors, international conflicts and the development of resistance to chemotherapy could increase the cases of leishmaniasis [3] .
The epidemiology and clinical features of leishmaniasis are highly variable due to the interplay of numerous factors in the parasites, vectors, host, and environments involved. Three principal clinical manifestations are recognized in leishmaniasis: cutaneous, mucocutaneous and visceral [4] . Primary prevention relies on managed control of the maintenance host and sandfly bite prevention measures. Secondary and tertiary prevention are dependent on medical assistance using the clinical guidelines [5] .
Currently, there is no immunoprotection available, although prospects for a vaccine remain high [6] . The main drugs to treat this disease are derivatives of pentavalent antimonial compounds (sodium stibogluconate and meglumine antimoniate), amphotericin B, and pentamidine [7, 8] . However, theses agents are far from ideal. Problems associated with the most commonly used drugs are: toxicity, parenteral administration, drug resistance and high cost [9] . Miltefosine is the only oral antileishmanial drug available, but pregnant women can not be given this compound due to its teratogenic effects [10] . For all the reasons previously mentioned, leishmaniasis continues to take an enormous toll on human health, particularly in endemic areas.
Many people in rural areas depend largely on popular treatments to alleviate the symptoms [11] . In traditional medicine, the most common treatment consists of the use of plants, which are potential sources of wide chemistry with a remarkable diversity, and are readily accessible in nature. Recently, the Tropical Diseases Program of the World Health Organization (TDR/WHO) with the Drug Discovery Research Program has considered the pharmacological investigation of plants to be a priority [12] .
Our laboratory has initiated and developed original investigations on alternative compounds to control the growth of Leishmania, with the objective to validate traditional medicine, as well as search for plant-derived drugs that could lead to new strategies for treatment of leishmaniasis. We began from the selection of plants with ethnomedical uses. Several studies have been addressed to recover the traditional expertise. Franca et al, in 1996, reported some plants used in the treatment of leishmanial ulcers [13] . We centered our attention on Chenopodium ambrosioides for three reasons: (i) It is an aromatic herb with a large history of use in the population; (ii) in the course of screening for leishmanicidal compounds, we found promising pharmacological results with the essential oil; and (iii) it is easily cultivated. A review of the experimental results with this product on the Leishmania parasite is presented in this article.
Chemical properties and composition of the essential oil from C. ambrosioides: The essential oil was obtained by distillation, under laboratory conditions, of the aerial parts of the plant. The efficiency was approximately 1% and the density of the essential oil was 0.8893 g/mL. The composition of the essential oil was determined by high resolution gas chromatography-mass spectrometry (HRGC-MS). The chromatogram showed 68 peaks and the nine major components were identified as carvacrol (62.4%), ascaridole (22.5%), caryophyllene oxide (5.6%), apiole (2.0%), isoascaridole (1.9%), hexyl tiglate (1.0%), p-cymene (0.8%), Δ 4 -carene (0.8%) and neomenthyl acetate (0.6%) [14] .
Chenopodium ambrosioides:
C. ambrosioides, popularly know as "apazote" in Cuba, is an aromatic plant, with its branched stem often prostrated. It is an annual or biannual herb, between 80 and 100 cm in height, with centuplicated leaves, which are oblonglanceolate and serrated, with small green flowers in dense terminal panicles of glomerules, each with five sepals. The plant is sylvan and grows in all geographic area of Cuba. A voucher specimen (No. 4639) is kept at the Experimental Station of Medicinal Plants "Dr. Juan Tomás Roig", Cuba [14] .
Antileishmanial in vitro studies: In-vitro activities of chenopodium oil against Leishmania amazonensis, the causal agent of cutaneous leishmaniasis, were determined. The growth of promastigotes and intracellular amastigotes forms of the parasite was inhibited by 100% at concentrations of 28 and 16 µg/mL, respectively. The 50% inhibitory concentration (IC 50 ) was determined to be 3.7 µg/mL against promastigotes and 4.6 µg/mL against amastigotes [14] . Surprisingly, the IC 50 values of the essential oil were similar against both forms of L. donovani (IC 50 promastigotes = 4.5 µg/mL and IC 50 amastigotes = 5.1 µg/mL), the causal agent of visceral leishmaniasis [15] .
Antileishmanial in vivo studies:
An initial experiment was carried out in order to evaluate the activity of chenopodium oil against an experimental model of cutaneous leishmaniasis, caused by L. amazonensis in BALB/c mice [14] . In this case, the objective was to validate the in-vitro activity previously obtained. Animals were infected and treatment began 15 days after inoculation. A significant reduction (P < 0.05) in the size of the lesions was observed in animals treated with 30 mg/Kg of the essential oil, in comparison with placebo groups of animals ( Figure 1 ). A second experiment was performed to compare the activity of chenopodium oil after either intraperitoneal or oral administration [16] . The treatment started 30 days after inoculation of parasites and animals received two cycles of treatment for 15 days. The mice treated with the essential oil by the oral route developed significantly similar lesions (P > 0.05) to those in mice treated by Figure 2 ). Nevertheless, from day 75 post-infection, an increase of the lesion size in animals treated by the oral route was observed. Toxicological evidence: Preliminary experiments were carried out to examine the toxicity of chenopodium oil in-vitro and in animal models. The essential oil showed an IC 50 of 58.8 μg/mL against peritoneal macrophages from BALB/c mice [14] .
The 50% lethal dose (LD 50 ) was 100 mg/Kg of the essential oil after one administration by the intraperitoneal route in BALB/c mice. Then, we determined the maximum tolerated dose (MTD), which is the dose that does not cause either death or weight loss in more than 10% of the mice treated during 15 days by the intraperitoneal route. The treatment of animals with a dose of 60 mg/Kg caused 100% mortality before the end of the treatment. The group of mice treated with 15 and 30 mg/kg did not show death and the loss of weight was small ( Table  1 ). The MTD selected was 30 mg/Kg/day by the intraperitoneal route [14] .
In order to compare the intraperitoneal with the oral route, gross-pathological changes in the thoracic and abdominal cavity was verified after 15 administrations of 30 mg/Kg/day of the essential oil. Intraperitoneal administration caused some perforations in the peritoneal cavity. Oral treatment did not show signs of toxicity [16] .
Resistance level of the parasite after treatment:
Isolates of Leishmania parasites from BALB/c mice were treated with two cycles of 30 mg/Kg/day of chenopodium oil during 15 days by intraperitoneal and oral routes [16] . Promastigotes showed similar susceptibility compared with the wild type promastigotes of reference strains (Table 2) . 
Synergistic effect:
The incubation of the essential oil from C. ambrosioides in conjunction with pentamidine shows a synergic activity against promastigotes of L. amazonensis (Table 3) . This result was demonstrated throughout isobologram analyses. However, an indifferent effect has been found for combinations of either meglunine antimoniate or amphotericin B and the essential oil [17] .
General considerations: Essential oils are aromatic oily liquids obtained from plant material, which were used at first as fragrances in perfume, but they are perceived to be alternative medicines due to their protective roles. Different pharmacological properties have been explored related to the function of the compounds in the plant [18] . However, there are few reports about the antileishmanial effects of essential oils. Our recent studies provide evidence that the essential oil from C. ambrosioides can constitute a promising alternative to the development of a new therapy against leishmaniasis. Previous reports have described ascaridole as the major constituent of the essential oil from Brazil and Canada [19, 20] . This endoperoxide is responsible for the anthelmintic effect, which was demonstrated by Smillie and Pessoa in 1924 [21] . However, the chemical analysis carried out in our study did not identify ascaridole as the main component. One reason could be the known variation in the chemical composition of plants, according to the geographic area. Fester et al found between 16 to 20% of ascaridole in the essential oil from plants collected in Cordoba, Argentina [22] . Surprisingly, the IC 50 value for the promastigotes and amastigotes of L. amazonensis were similar (P > 0.05) to that found for L. donovani. Taking this result into account, we should consider the possibility that this essential oil acts either on a molecule or inhibits a metabolic pathway conserved in the Leishmania genus, which might be equally important for the viability of both morphophysiological forms. Another possible explanation is that the activity of the essential oil on both parasitic forms is the result of action of several compounds present in the oil, which could act on different molecules or metabolic pathways of Leishmania.
The mechanism of action by which the essential oil kills Leishmania is still unknown. However, some authors have shown that ascaridole generates free radicals, which act on parasitic DNA. This property is due to cleavage of the O-O bond in the endoperoxide [23a-23c] . Other experiments are necessary to search for the mechanism of action of the essential oil.
The intraperitoneal route was the most effective in controlling the disease after its establishment. Oral administration of the essential oil produced the same effect as treatment of the mice by the intraperitoneal route, except for a slight transient recrudescence in lesion size between 8 and 12 week post-infection. The effectiveness of the oral route results in a good absorption of the essential oil through the gastrointestinal tract. For that reason, it must also be assumed that the principal active agent was metabolized at low levels and is transported via the systemic circulation from the intestinal mucosa to the infected tissue. However, a partial loss of the drug may occur due to exchange interactions through different compartments such as the blood, the liver and others.
Preliminary experiments were carried out to examine the potential toxicity of the essential oil in-vitro and in-vivo. The essential oil showed a moderate toxicity against mouse peritoneal macrophages, approximately 15-fold more selective against Leishmania parasite compared to mammalian cells. This result suggests that the product may be safe for host cells. Oral administration of essential oil in BALB/c mice did not exhibit any observable signs of toxicity in these animals, which could facilitate long term treatment, in order to produce a consistent protection against cutaneous leishmaniasis.
Complete cure of the animals treated with the essential oil did not occur. However, while untreated animals develop the inexorable disease, mice treated with the essential oil by the intraperitoneal and oral routes had small lesions and low parasite burden. The model of cutaneous leishmaniasis due to L. amazonensis is not a perfect model, because it is a highly virulent strain and causes a disseminating, "noncure" and fatal diseases in BALB/c mice [23d].
Leishmania parasites are evolutionarily successful organisms, and they must develop highly sophisticated actions to combat the host's killing mechanisms [24] , that include the immune response of the host and chemotherapy.
The development of drug resistance in the parasites is another major impediment in the successful treatment with conventional drugs [25] . In our work, the resistance index was less than twice compared with the wild type strains. We can thus assume that the drug pressure received by strains was very low to develop the expression of other phenotypes like drug resistance. In others studies, a high resistance level was found in L. infantum isolates from dogs that received two treatment cycle of meglumine /Kg/12 h/10 days) [26] . As part of a series of studies on the antileishmanial activity of some compounds (miltefosine, atovaquone), promastigote resistant lines have been selected by stepwise increases in drug pressure in-vitro. In this study, selection of resistant lines in vitro had shown a high level of resistance, but this induction had been found after five or more treatments [27, 28] .
After increased unresponsiveness to most of the monotherapeutic regimens, combination therapy has found new scope in the treatment of both cutaneous and visceral leishmaniasis [29] . Additionally, the combination of antileishmanial drugs could reduce the potential toxic side effects and prevent drug resistance. For these reasons, it is important to critically evaluate the role of combination therapy as new data. Several works have shown that some drugs increased their antileishmanial effect in conjunction with new antileishmanial agents.
Synergism among antileishmanial agents might occur in one of several ways. The inhibition of different stages of the same biochemical pathway represents one type of mechanism of synergism [30] . It is possible that this mechanism could explain the synergistic effect found between pentamidine and the essential oil. Multiple mechanisms of action had been proposed for pentamidine in kinetoplastid parasites, including DNA binding [31, 32] . On the other hand, the exact mechanism of action of the essential oil is not known, but some authors hypothesized that ascaridole (endoperoxide), an active molecule, generates free radicals that can act on parasitic DNA [23a,23b] . Investigations are in progress in our laboratory to identify the mechanism involved in the antileishmanial activity. We observed electronic perturbations in the essential oil after increased amounts of Leishmania DNA, due to a hypochromism effect (data not shown). These perturbations could suggest an interaction of the DNA with the compounds present in the essential oil.
Although we are thinking in terms of a correlation between DNA binding affinity and synergism observed, this may not be the only factor contributing to increase of antileishmanial activity.
Conclusions:
Plant essential oils can be used as alternatives to current antiparasitic therapies [33] . Our results demonstrated that chenopodium oil is effective in-vitro and in-vivo against Leishmania, in addition to having acceptable biological properties (easily extracted oil, bioavailability by oral route, toxicity or tolerability of the animals, the small resistance induced, and the synergistic effect in conjunction with pentamidine). These results are in concordance to standard criteria (Table 5) , shown by Pink et al, concerning the drug discovery process [9] . The promising results and the relative cost of the product are important considerations that suggest continuation of the study of the essential oil from C. ambrosioides as an antileishmanial drug for people in developing countries. Future studies should be performed in order to develop a formulation with the desired pharmacokinetic and toxicological properties, accessible to endemic populations.
